MNOV trade ideas
Vaccine Joint Development with BioComo and Mie University JapanMediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
through our joint development with MediciNova, we will proceed with further non-clinical and clinical trial development as quickly as possible globally and not only in Japan.
We are confident that the BC-PIV SARS-CoV-2 vaccine will be successful and hope that this vaccine will be available in a clinical setting as soon as possible and will be the “gospel” for the people in the world.”
www.globenewswire.com
www.fool.com
$MNOV can rise in the next daysContextual immersion trading strategy idea.
The demand for shares of MediciNova looks higher than the supply.
The company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs.
Due to the spread of COVID-19, the demand for the company`s services rose.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $4,41;
stop-loss — $4,21.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!